TeraImmune

KEI Comments to NIH on Exclusive License to TeraImmune for T-cell Therapy for Multiple Sclerosis

Posted on by KEI Staff

(Update: The NIH provided a response to our questions and comments on February 28, 2022) On February 9, 2022, Knowledge Ecology International (KEI) filed comments with the National Institutes of Health regarding the “Prospective Grant of Exclusive Patent License: Development… Continue Reading →

KEI Comments Regarding NIH Exclusive License to TeraImmune for T Cell Therapy

Posted on by KEI Staff

(UPDATE: The NIH provided a response to our comments on February 25, 2020) On February 3, 2020, Knowledge Ecology International (KEI) submitted comments to the “Prospective Grant of Exclusive Patent License: Development of Regulatory T-Cell Therapies for the Treatment of… Continue Reading →